One goal of the Longitudinal Early-onset Alzheimer’s Disease Study (LEADS) is to investigate the genetic etiology of early onset (40–64 years) cognitive impairment. Toward this goal, LEADS participants are screened for known pathogenic variants.
LEADS amyloid-positive early-onset Alzheimer’s disease (EOAD) or negative early-onset non-AD (EOnonAD) cases were whole exome sequenced (N = 299). Pathogenic variant frequency in APP, PSEN1, PSEN2, GRN, MAPT, and C9ORF72 was assessed for EOAD and EOnonAD. Gene burden testing was performed in cases compared to similar-age cognitively normal controls in the Parkinson’s Progression Markers Initiative (PPMI) study.
Previously reported pathogenic variants in the six genes were identified in 1.35% of EOAD (3/223) and 6.58% of EOnonAD (5/76). No genes showed enrichment for carriers of rare functional variants in LEADS cases.
Results suggest that LEADS is enriched for novel genetic causative variants, as previously reported variants are not observed in most cases.
Sequencing identified eight cognitively impaired pathogenic variant carriers.
Pathogenic variants were identified in PSEN1, GRN, MAPT, and C9ORF72.
Rare variants were not enriched in APP, PSEN1/2, GRN, and MAPT.
The Longitudinal Early-onset Alzheimer’s Disease Study (LEADS) is a key resource for early-onset Alzheimer’s genetic research
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Kelly N. H. Nudelman,
Jeffrey L. Dage,
Kelley M. Faber,
Dustin B. Hammers,
DIAN/DIAN‐TU Clinical/Genetics Committee,
Walter A. Kukull,
Melissa E. Murray,
Arthur W. Toga,
Gregory S. Day,
Neill R. Graff‐Radford,
Lawrence S. Honig,
David T. Jones,
Joseph C. Masdeu,
Chiadi U. Onyike,
Sharon J. Sha,
R. Scott Turner,
Thomas S. Wingo,
David A. Wolk,
Maria C. Carrillo,
Bradford C. Dickerson,
Gil D. Rabinovici,
Liana G. Apostolova,
the LEADS Consortium | October 6, 2023